Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression
This study provides a comprehensive evaluation of CLDN18.2 status and its correlation with the clinicopathologic characteristics of patients with stages II-IV GC in Korea and with crucial biomarkers. It may be valuable for guiding future drug development, expanding treatment options, and ultimately improving patient outcomes in GC.
Authors
- Do Joong Park (ORCID: https://orcid.org/0000-0001-9644-6127)
- Yoonjin Kwak (ORCID: https://orcid.org/0000-0001-5314-2465)
- Daeyoung Han
- Hye Jung Hwang
- Hyuk‐Joon Lee (ORCID: https://orcid.org/0000-0002-9530-647X)
- Seock‐Ah Im (ORCID: https://orcid.org/0000-0002-5396-6533)
- Hye Seung Lee (ORCID: https://orcid.org/0000-0002-1667-7986)
- Soo Kyung Nam (ORCID: https://orcid.org/0000-0002-4372-1516)
- Hyeon Jeong Oh (ORCID: https://orcid.org/0000-0002-9998-3988)
- Tae-Yong Kim (ORCID: https://orcid.org/0000-0002-4147-3635)
- Han‐Kwang Yang (ORCID: https://orcid.org/0000-0003-3495-3048)
- Seong-Ho Kong
- Do-Youn Oh
Institutions
- Seoul National University (KR)
- Cancer Research Institute (US)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- National University College (PR)
- Astellas Pharma (South Korea) (KR)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-09-21
- DOI
- https://doi.org/10.1093/oncolo/oyae238
- Citations
- 20
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 8.38
Funders
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders